Switch theme
Sign up to access all valuation multiples
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
2016
274
LTM Revenue $7.0M
LTM EBITDA -$25.3M
$65.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Creo Medical Group has a last 12-month revenue (LTM) of $7.0M and a last 12-month EBITDA of -$25.3M.
In the most recent fiscal year, Creo Medical Group achieved revenue of $5.5M and an EBITDA of -$35.6M.
Creo Medical Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Creo Medical Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.0M | XXX | $5.5M | XXX | XXX | XXX |
| Gross Profit | $3.7M | XXX | $2.6M | XXX | XXX | XXX |
| Gross Margin | 53% | XXX | 48% | XXX | XXX | XXX |
| EBITDA | -$25.3M | XXX | -$35.6M | XXX | XXX | XXX |
| EBITDA Margin | -361% | XXX | -652% | XXX | XXX | XXX |
| EBIT | -$30.7M | XXX | -$39.3M | XXX | XXX | XXX |
| EBIT Margin | -439% | XXX | -720% | XXX | XXX | XXX |
| Net Profit | -$29.4M | XXX | -$39.2M | XXX | XXX | XXX |
| Net Margin | -420% | XXX | -717% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 17, 2025, Creo Medical Group's stock price is GBP 0 (or $0).
Creo Medical Group has current market cap of GBP 52.1M (or $71.1M), and EV of GBP 47.8M (or $65.2M).
See Creo Medical Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $65.2M | $71.1M | XXX | XXX | XXX | XXX | $-0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 17, 2025, Creo Medical Group has market cap of $71.1M and EV of $65.2M.
Creo Medical Group's trades at 11.9x EV/Revenue multiple, and -1.8x EV/EBITDA.
Equity research analysts estimate Creo Medical Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Creo Medical Group has a P/E ratio of -2.4x.
See valuation multiples for Creo Medical Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $71.1M | XXX | $71.1M | XXX | XXX | XXX |
| EV (current) | $65.2M | XXX | $65.2M | XXX | XXX | XXX |
| EV/Revenue | 9.3x | XXX | 11.9x | XXX | XXX | XXX |
| EV/EBITDA | -2.6x | XXX | -1.8x | XXX | XXX | XXX |
| EV/EBIT | -2.1x | XXX | -1.7x | XXX | XXX | XXX |
| EV/Gross Profit | 17.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.4x | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | -2.9x | XXX | -2.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCreo Medical Group's last 12 month revenue growth is 63%
Creo Medical Group's revenue per employee in the last FY averaged $20K, while opex per employee averaged $0.2M for the same period.
Creo Medical Group's rule of 40 is -5% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Creo Medical Group's rule of X is -204% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Creo Medical Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 63% | XXX | 60% | XXX | XXX | XXX |
| EBITDA Margin | -361% | XXX | -652% | XXX | XXX | XXX |
| EBITDA Growth | -34% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -5% | XXX | -590% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -204% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $20K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 768% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Creo Medical Group acquired XXX companies to date.
Last acquisition by Creo Medical Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Creo Medical Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Creo Medical Group founded? | Creo Medical Group was founded in 2016. |
| Where is Creo Medical Group headquartered? | Creo Medical Group is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Creo Medical Group have? | As of today, Creo Medical Group has 274 employees. |
| Who is the CEO of Creo Medical Group? | Creo Medical Group's CEO is Mr. Craig Jonathan Gulliford. |
| Is Creo Medical Group publicy listed? | Yes, Creo Medical Group is a public company listed on LON. |
| What is the stock symbol of Creo Medical Group? | Creo Medical Group trades under CREO ticker. |
| When did Creo Medical Group go public? | Creo Medical Group went public in 2016. |
| Who are competitors of Creo Medical Group? | Similar companies to Creo Medical Group include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Creo Medical Group? | Creo Medical Group's current market cap is $71.1M |
| What is the current revenue of Creo Medical Group? | Creo Medical Group's last 12 months revenue is $7.0M. |
| What is the current revenue growth of Creo Medical Group? | Creo Medical Group revenue growth (NTM/LTM) is 63%. |
| What is the current EV/Revenue multiple of Creo Medical Group? | Current revenue multiple of Creo Medical Group is 9.3x. |
| Is Creo Medical Group profitable? | Yes, Creo Medical Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Creo Medical Group? | Creo Medical Group's last 12 months EBITDA is -$25.3M. |
| What is Creo Medical Group's EBITDA margin? | Creo Medical Group's last 12 months EBITDA margin is -361%. |
| What is the current EV/EBITDA multiple of Creo Medical Group? | Current EBITDA multiple of Creo Medical Group is -2.6x. |
| What is the current FCF of Creo Medical Group? | Creo Medical Group's last 12 months FCF is -$22.6M. |
| What is Creo Medical Group's FCF margin? | Creo Medical Group's last 12 months FCF margin is -322%. |
| What is the current EV/FCF multiple of Creo Medical Group? | Current FCF multiple of Creo Medical Group is -2.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
